Literature DB >> 23441057

PedsQL™ sickle cell disease module: feasibility, reliability, and validity.

Julie A Panepinto1, Sylvia Torres, Cristiane B Bendo, Timothy L McCavit, Bogdan Dinu, Sandra Sherman-Bien, Christy Bemrich-Stolz, James W Varni.   

Abstract

BACKGROUND: Sickle cell disease (SCD) is an inherited chronic disease that is characterized by complications such as recurrent painful vaso-occlusive events that require frequent hospitalizations and contribute to early mortality. The objective of the study was to report on the initial measurement properties of the new PedsQL™ SCD Module for pediatric patient self-report ages 5-18 years and parent proxy-report for ages 2-18 years. PROCEDURE: The 43-item PedsQL™ SCD Module was completed in a multisite study by 243 pediatric patients with SCD and 313 parents. Participants also completed the PedsQL™ 4.0 Generic Core Scales and PedsQL™ Multidimensional Fatigue Scale.
RESULTS: The PedsQL™ SCD Module Scales evidenced excellent feasibility, excellent reliability for the Total Scale Scores (patient self-report α = 0.95; parent proxy-report α = 0.97), and good reliability for the nine individual scales (patient self-report α = 0.69-0.90; parent proxy-report α = 0.83-0.97). Intercorrelations with the PedsQL™ Generic Core Scales and PedsQL™ Multidimensional Fatigue Scales were medium (0.30) to large (0.50) range, supporting construct validity. PedsQL™ SCD Module Scale Scores were generally worse for patients with severe versus mild disease. Confirmatory factor analysis demonstrated an acceptable to excellent model fit.
CONCLUSIONS: The PedsQL™ SCD Module demonstrated acceptable measurement properties. The PedsQL™ SCD Module may be utilized in the evaluation of SCD-specific health-related quality of life in clinical research and practice. In conjunction with the PedsQL™ Generic Core Scales and the PedsQL™ Multidimensional Fatigue Scale, the PedsQL™ SCD Module will facilitate the understanding of the health and well-being of children with SCD.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23441057      PMCID: PMC4412167          DOI: 10.1002/pbc.24491

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  37 in total

1.  Responsiveness of the PedsQL to pain-related changes in health-related quality of life in pediatric sickle cell disease.

Authors:  Alyssa M Schlenz; Jeffrey Schatz; Catherine B McClellan; Carla W Roberts
Journal:  J Pediatr Psychol       Date:  2012-03-30

2.  Health-related quality of life in children and adolescents with sickle cell disease.

Authors:  Juanita Conkin Dale; Cindy J Cochran; Lonnie Roy; Ethel Jernigan; George R Buchanan
Journal:  J Pediatr Health Care       Date:  2010-04-02       Impact factor: 1.812

3.  PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations.

Authors:  J W Varni; M Seid; P S Kurtin
Journal:  Med Care       Date:  2001-08       Impact factor: 2.983

4.  The PedsQL Brain Tumor Module: initial reliability and validity.

Authors:  Stephanie N Palmer; Kathleen A Meeske; Ernest R Katz; Tasha M Burwinkle; James W Varni
Journal:  Pediatr Blood Cancer       Date:  2007-09       Impact factor: 3.167

5.  The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module.

Authors:  James W Varni; Michael Seid; Tara Smith Knight; Tasha Burwinkle; Joy Brown; Ilona S Szer
Journal:  Arthritis Rheum       Date:  2002-03

6.  Perception of quality of life by patients, partners and treating physicians.

Authors:  K A Wilson; A J Dowling; M Abdolell; I F Tannock
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

7.  The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module.

Authors:  James W Varni; Tasha M Burwinkle; Ernest R Katz; Kathy Meeske; Paige Dickinson
Journal:  Cancer       Date:  2002-04-01       Impact factor: 6.860

8.  The PedsQL in type 1 and type 2 diabetes: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales and type 1 Diabetes Module.

Authors:  James W Varni; Tasha M Burwinkle; Jenifer R Jacobs; Michael Gottschalk; Francine Kaufman; Kenneth L Jones
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

9.  Validity of the child health questionnaire for use in children with sickle cell disease.

Authors:  Julie A Panepinto; Kerry M O'Mahar; Michael R DeBaun; Kimberly M Rennie; J Paul Scott
Journal:  J Pediatr Hematol Oncol       Date:  2004-09       Impact factor: 1.289

Review 10.  Parent-child agreement across child health-related quality of life instruments: a review of the literature.

Authors:  Penney Upton; Joanne Lawford; Christine Eiser
Journal:  Qual Life Res       Date:  2008-06-03       Impact factor: 4.147

View more
  48 in total

1.  Brief Screening Measures Identify Risk for Psychological Difficulties Among Children with Sickle Cell Disease.

Authors:  Anna M Hood; Ilana Reife; Allison A King; Desiree A White
Journal:  J Clin Psychol Med Settings       Date:  2020-12

2.  Greater number of perceived barriers to hydroxyurea associated with poorer health-related quality of life in youth with sickle cell disease.

Authors:  Arlene Smaldone; Deepa Manwani; Nancy S Green
Journal:  Pediatr Blood Cancer       Date:  2019-04-02       Impact factor: 3.167

3.  PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity.

Authors:  Kavitha Nutakki; James W Varni; Nancy L Swigonski
Journal:  J Neurooncol       Date:  2017-12-22       Impact factor: 4.130

4.  Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy.

Authors:  Lauren M Beverung; John J Strouse; Monica L Hulbert; Kathleen Neville; Robert I Liem; Baba Inusa; Beng Fuh; Allison King; Emily Riehm Meier; James Casella; Michael R DeBaun; Julie A Panepinto
Journal:  Am J Hematol       Date:  2015-02       Impact factor: 10.047

5.  Care Coordination for Children With Sickle Cell Disease: A Longitudinal Study of Parent Perspectives and Acute Care Utilization.

Authors:  Tiffany L Rattler; Annette M Walder; Hua Feng; Jean L Raphael
Journal:  Am J Prev Med       Date:  2016-07       Impact factor: 5.043

6.  Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.

Authors:  Arlene Smaldone; Sally Findley; Suzanne Bakken; L Adriana Matiz; Susan L Rosenthal; Haomiao Jia; Sergio Matos; Deepa Manwani; Nancy S Green
Journal:  Contemp Clin Trials       Date:  2016-06-17       Impact factor: 2.226

7.  Empirically Derived Profiles of Health-Related Quality of Life in Youth and Young Adults with Sickle Cell Disease.

Authors:  Mary E Keenan; Megan Loew; Kristoffer S Berlin; Jason Hodges; Nicole M Alberts; Jane S Hankins; Jerlym S Porter
Journal:  J Pediatr Psychol       Date:  2021-03-18

8.  HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.

Authors:  Arlene Smaldone; Sally Findley; Deepa Manwani; Haomiao Jia; Nancy S Green
Journal:  J Pediatr       Date:  2018-03-20       Impact factor: 4.406

9.  Changes in Pain and Psychosocial Functioning and Transition to Chronic Pain in Pediatric Sickle Cell Disease: A Cohort Follow-up Study.

Authors:  Soumitri Sil; Lindsey L Cohen; Nitya Bakshi; Amanda Watt; Morgan Hathaway; Farida Abudulai; Carlton Dampier
Journal:  Clin J Pain       Date:  2020-06       Impact factor: 3.442

Review 10.  Key Components of Pain Management for Children and Adults with Sickle Cell Disease.

Authors:  Amanda M Brandow; Michael R DeBaun
Journal:  Hematol Oncol Clin North Am       Date:  2018-06       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.